6 completed, 1 recruiting, 1 unknown. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Recruiting 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
Follow Boostrix: new trials by email Literature Review of Boostrix trials Research Report on Boostrix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults GC3111B, Boostrix® - Tetanus-diphtheria-acellular Pertussis (Tdap) | Phase 1 / Phase 2 | Recruiting | GC Biopharma Corp | 120 | 2025-06-05 | 2025-07-10 |
| Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine - Typhoid Fever | Phase 1 | Completed | GlaxoSmithKline | 97 | 2022-11-28 | 2025-01-24 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| Viaskin Pertussis Vaccine Trial Viaskin PT 25 mcg, Viaskin PT 50 mcg, Viaskin PT Placebo - Whooping Cough | Phase 1 | Completed | DBV Technologies | 102 | 2016-09-05 | 2020-03-02 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
| A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants Ixekizumab, Boostrix®, Pneumovax®23 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 84 | 2015-09-01 | 2017-01-06 |
| Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1) aP booster, TdaP booster, Licensed TdaP booster (Boostrix®) - Pertussis | Phase 1 | Completed | Novartis | 315 | 2015-04-01 | 2016-03-24 |
Whooping Cough (3) · Diarrhea (1) · Diphtheria (1) · Dysentery, Bacillary (1) · Paratyphoid Fever (1) · Salmonella Infections (1) · Tetanus (1) · Typhoid Fever (1)
GlaxoSmithKline (3) · DBV Technologies (1) · Eli Lilly and Company (1) · GC Biopharma Corp (1) · Green Cross Corporation (1) · Novartis (1)
Belgium (4) · South Korea (2) · Kenya (1) · Malawi (1) · Switzerland (1) · United States (1)
PMID 29116597, PMID 29172945, PMID 32896653, PMID 38853614, PMID 41587557, PMID 42234814
2014 (1)